Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53

British Journal of Cancer

Volumn 79, Issue 7-8, 1999, Pages 1111-1120

  Wyllie, F S ^a   Haughton, M F ^a   Rowson, J M ^a   Wynford Thomas, D ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Differentiation; Iso genic; p53; Thyroid; Tumour progression

Indexed keywords

BLEOMYCIN; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; MUTANT PROTEIN; PROTEIN P21; PROTEIN P53; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN INDUCTION; STRESS; THYROID CANCER; WART VIRUS;

CARCINOMA, PAPILLARY; CELL COUNT; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; G1 PHASE; G2 PHASE; GENE DELETION; GENES, P53; GENETIC VECTORS; GENOTYPE; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PAIRED BOX TRANSCRIPTION FACTORS; PHENOTYPE; REPRESSOR PROTEINS; THYROID NEOPLASMS; TIME FACTORS; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033052474     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690177     Document Type: Article

References (67)

1. Almog N and Rotter V (1997) Involvement of p53 in cell differentiation and development. Biochim Biophys Acta 133: F1-F27
2. Aloni-Grinstein R, Zan-Bar I, Alboum R, Goldfinger N and Rotter V (1993) Wild-type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 8: 3297-3305
3. 2 arrest-dependent immunoglobulin κ light chain gene expression. EMBO J 14: 1392-1401
4. Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915
5. Barnes DM, Dublin EA, Fisher CJ, Levison DA and Millis RR (1993) Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Human Pathol 24: 469-476
6. Battista S, Martelli ML, Fedele M, Chiappetta G, Trapasso F, De Vita G, Battaglia C, Santoro M, Viglietto G, Fagin JA and Fusco A (1995) A mutated p53 gene alters thyroid cell differentiation. Oncogene 11: 2029-2037
7. Bi S, Barton CM, Lemoíne NR, Cross NCP and Goldman JM (1994) Retroviral transduction of Philadelphia-positive chronic myeloid leukaemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation. Exp Hematol 22: 95-99
8. Blaydes JP, Schlumberger M, Wynford-Thomas D and Wyllie FS (1995) Interaction between p53 andTGFb1 in control of epithelial cell proliferation. Oncogene 10: 307-317
9. Bond JA, Dawson T, Lemoine NR and Wynford-Thomas D (1992) Effect of serum growth factors and phorbol ester un growth and survival of human thyroid epithelial cells expressing mutant ras. Mol Carcinogen 5: 129-135
10. Bond JA, Blaydes JP, Rowson J, Haughton MF, Smith JR, Wynford-Thomas D and Wyllie FS (1995) Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res 55: 2404-2409
11. Bond JA, Ness GO, Rowson J, Ivan M, White D and Wynford-Thomas D (1996) Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: An epigenetic mechanism of tumour progression? Int J Cancer 67: 563-572
12. Brash DE, Reddel RR, Quanrad M, Yang K, Farrell MP and Harris CC (1987) Strontium phosphate transfection of human cells in primary culture: stable expression of the Simian virus 40 large-T-Antigen gene in primary human bronchial epithelial cells. Mol Cell Biol 7: 2031-2034
13. Brenner L, Munozantonia T, Vellucci VF, Zhou Z-L and Reiss M (1994) Wild-type p53 tumour suppressor gene restores differentiation of human squamous carcinoma cells but not the response to transforming growth factor-beta. Cell Growth Diff 4: 993-1004
14. Brocas H, Christophe D, Pohl V and Vassart G (1982) Cloning of human thyroglobulin complementary DNA. FEBS Lett 137: 189-192
15. Burns JS, Lemoine L, Lemoine NR, Williams ED and Wynford-Thomas D (1989) Thyroid epithelial cell transformation by a retroviral vector expressing SV40 large T. Br J Cancer 59: 755-760
16. Carcangiu ML, Steeper T, Zampi G and Rosai J (1985) Anaplastic thyroid carcinoma. Am J Cell Pathol 83: 135-158
17. Challeton C, Branea F, Schlumberger M, Gaillard N, DeVathaire F, Badie C, Antonini P and Parmentier C (1997) Characterisation and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumours. Int J Radiat Oncol Biol Physics 37: 163-169
18. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B and Friend SH (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772-5781
19. Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V and Schwartz M (1996) p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 16: 5178-5185
20. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174
21. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R and Damante G (1994) Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 54: 4744-4749
22. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang S-H and Koeffler HP (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184
23. Fagin JA, S-H, T, Zeki K, Di Lauro R, Fusco A and Gonsky R (1996) Re-expression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 56: 765-771
24. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ and O'Connor PM (1995) Disruption of p53 function sensitises breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654
25. Fearon ER and Vogelstein BA (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767
26. Feinslein E, Gale RP, Reed J and Canaani E (1992) Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 7: 1853-1857
27. Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW and Harris CC (1995) Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10: 2103-2111
28. Friedlander P, Haupt Y, Prives C and Oren M (1996) A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16: 4961-4971
29. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T and Terada M (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cant er Res 52: 1393-1398
30. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
31. Guazzi S, Price M, De Felice M. Damante G, Mattei M-G and Di Lauro R (1990) Thyroid nuclear factor 1 (TTF1) contains a homeodomain and displays a novel DNA binding specificity. EMBO J 9: 3631-3639
32. Halbert CL, Demers GW and Galloway DA (1991) The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 65: 473-478
33. Halevy O (1993) p53 gene is up-regulated during skeletal muscle cell differentiation. Biochem Biophys Res Commun 192: 714-719
34. Harlow E, Crawford LV, Pim DC and Williamson NM (1981) Monoclonal antibodies specific for simian virus 40 tumour antigens. J Virol 39: 861-869
35. Hsu TC, Johnston DA, Cherry LM, Ramkisson D, Schantz SP, Jessup JH. Winn RJ, Shirley L and Furlong C (1989) Sensitivity to genotoxic effects of bleomycin in humans; possible relationship to environmental carcinogenesis. Int J Cancer 43: 403-109
36. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N and Akiyama M (1992) Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369-1371
37. Johnson P, Gray D, Mowat M and Benchimol S (1991) Expression of wild-type p53 is not compatible with continued grow th of p53-negative tumour cells. Mol Cell Biol 11: 1-11
38. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
39. Kemp CJ, Donehower LA, Bradley A and Balmain A (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumours. Cell 74: 813-822
40. Lavigeur A, Maltby V, Mock D, Rossant J, Pawson T and Bernstein A (1989) High incidence of lung, bone and lymphoid tumours in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9: 3982-3991
41. Libert F, Ruel J, Ludgate M, Swillens S, Alexander N, Vassart G and Dinsart C (1987) Complete nucleotide sequence of the human thyroperoxidase-microsomal antigen cDNA. Nucleic Acids Res 15: 6735
42. Libert F, Lefort A, Gerard C, Parmentier M, Perret J, Ludgate M, Dumont JE and Vassart G (1989) Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Commun 165: 1250-1255
43. Ludwig RL, Bates S and Vousden K (1996) Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 66: 4952-4960
44. McIlwratn AJ, Vasey PA, Ross GM and Brown R (1994) Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718-3722
45. Michalovitz D, Halevy O and Oren M (1991) p53 mutations: gains or losses? J Cell Biochem 45: 22-29
46. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A and Pontecorvi A (1997) p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 14: 729-740
47. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, Von Eschenbach AC and Conti CJ (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1669
48. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ and Kohn KW (1997) Characterisation of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300
49. Poleev A, Fickenscher H, Mundlos S, Winterpacht A, Zabel B, Fidler A, Gruss P and Plachov D (1992) PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development 116: 611-623
50. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
51. Shaulsky G, Goldfinger N, Peled A and Rotter V (1991) Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci USA 88: 8982-8986
52. Soddu S, Blandino G, Citro G, Scardigli R, Piaggio G, Ferber A, Calabretta B and Sacchi A (1994) Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 83: 2230-2237
53. Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M and Sacchi A (1996) Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol 134: 193-204
54. Southern PJ and Berg P (1982) Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol App Genet 1: 327-341
55. Weinberg WC, Azzoli CG, Chapman K, Levine AJ and Yuspa SH (1995) p53-mcdiated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 10: 2271-2279
56. Weinstein JN, Myers TG, O'Connor PM and Friend SH (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349
57. Williams AC, Miller JC, Collard TJ, Bracey TC, Cosulich S and Paraskeva C (1995) Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after γ irradiation. Oncogene 11: 141-149
58. Williams DW and Williams ED (1989) The pathology of follicular thyroid epithelial tumours. In Wynford-Thomas D and Williams ED (eds), Thyroid Tumours: Molecular Basis of Pathogenesis, pp. 57-65, Churchill Livingstone: Edinburgh
59. Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, Roher H-D, Williams ED and Wynford-Thomas D (1991) Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 6: 1693-1697
60. Wyllie FS, Lemoine NR, Williams ED and Wynford-Thomas D (1989) Structure and expression of nuclear oncogenes in multi-stage thyroid tumorigenesis. Br J Cancer 60: 561-565
61. Wyllie FS, Lemoine NR, Barton CM, Dawson T, Bond JA and Wynford-Thomas D (1993) Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinogen 7: 83-88
62. Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M and Wynford-Thomas D (1995) Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells. Oncogene 10: 49-59
63. Wynford-Thomas D (1993) Molecular genetics of thyroid cancer. Trends Endocrinol Metab 4: 224-232
64. Wynford-Thomas D (1996) p53: guardian of cellular senescence. J Pathol 180: 118-121
65. Wynford-Thomas D, Bond JA, Wyllie FS, Bums J, Williams ED, Jones T, Sheer D and Lemoine NR (1990) Conditional immortalisation of human thyroid epithelial cells: a tool for analysis of oncogene action. Mol Cell Biol 10: 5365-5377
66. Wynford-Thomas D, Jones CJ and Wyllie FS (1996) The tumour suppressor gene p53 as a regulator of proliferative life-span and tumour progression. Biol Signals 5: 139-153
67. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T and Brash DE (1994) Sunburn and p53 in the onset of skin cancer. Nature 372: 773-777